{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:17:49Z","timestamp":1788455869282,"version":"build-2803163510"},"reference-count":73,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Pancreatic adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited survival gains despite advances in systemic therapy. However, rapid expansion of biomarker-directed therapies, immunotherapy, and novel treatment modalities has created an increasingly complex clinical trial landscape. We aimed to characterize contemporary PDAC clinical development and identify emerging therapeutic trends. Methods: We performed a narrative review with a scoping approach of active PDAC clinical trials registered on ClinicalTrials.gov. Eligible studies were initiated between January 1, 2021, and February 16, 2026, and included recruiting, active, or not-yet-recruiting phase I\u2013III trials. Data extracted included trial phase, disease setting, therapeutic strategy, endpoints, enrollment, sponsorship, and late-phase development. Results: A total of 355 interventional trials were included. Most trials were phase I, phase I\/II, or phase II trials, with fewer than 10% being evaluated in phase II\/III or phase III development. Advanced or metastatic disease was the predominant setting. Chemotherapy remained the most frequently incorporated treatment modality, while molecularly targeted therapies were evaluated in 167 trials. KRAS\/RAS-directed approaches represented the largest targeted subgroup, although only daraxonrasib and setidegrasib reached phase III evaluation. Immunotherapy was evaluated in 139 trials, although only a limited number progressed to late-phase development, reflecting the immune-resistant biology of pancreatic adenocarcinoma. Additional areas of active investigation included Claudin 18.2-targeted therapies, MTAP-associated approaches, homologous recombination deficiency-directed strategies, CD73 inhibition, radiotherapy, local interventions, surgery-focused optimization, imaging-guided approaches, and supportive-care interventions. Industry organizations were listed as the lead sponsor for approximately half of all studies, while non-commercial organizations supported most remaining trials. Conclusions: The contemporary PDAC clinical trial landscape is characterized by broad therapeutic diversification but limited late-phase maturity. Chemotherapy remains the dominant treatment backbone, whereas KRAS\/RAS-directed therapies have emerged as the most advanced precision oncology strategy. Future progress will likely depend on successful integration of biomarker-selected therapies with established multidisciplinary treatment approaches, including optimized systemic therapy, local-control strategies, and supportive care.<\/jats:p>","DOI":"10.3390\/ph19091371","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:08:58Z","timestamp":1788142138000},"page":"1371","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary Landscape of Active Clinical Trials in Pancreatic Ductal Adenocarcinoma: A ClinicalTrials.gov\u2014Based Narrative Review with a Scoping Approach"],"prefix":"10.3390","volume":"19","author":[{"given":"Laura","family":"Rado\u0161","sequence":"first","affiliation":[{"name":"Tumor Clinic, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-9762","authenticated-orcid":false,"given":"Sara","family":"Matuli\u0107 \u010cubrani\u0107","sequence":"additional","affiliation":[{"name":"Tumor Clinic, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3388-4813","authenticated-orcid":false,"given":"Marin","family":"Gol\u010di\u0107","sequence":"additional","affiliation":[{"name":"Tumor Clinic, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia"},{"name":"Department of Oncology and Radiotherapy, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Sko\u010dili\u0107","sequence":"additional","affiliation":[{"name":"Tumor Clinic, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia"},{"name":"Department of Oncology and Radiotherapy, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Mikola\u0161evi\u0107","sequence":"additional","affiliation":[{"name":"Tumor Clinic, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia"},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-6600","authenticated-orcid":false,"given":"Andrej","family":"Belan\u010di\u0107","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Li, T., Lin, C., and Wang, W. (2025). Global, regional, and national burden of pancreatic cancer from 1990 to 2021, its attributable risk factors, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13597-z"},{"key":"ref_2","unstructured":"National Cancer Institute (2026, June 16). SEER Cancer Stat Facts: Pancreatic Cancer [Internet], Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Peshin, S., Takrori, E., Kodali, N.A., Bashir, F., and Singal, S. (2025). Advances in the management of pancreatic cancer: Current strategies and emerging therapies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157055"},{"key":"ref_4","unstructured":"National Comprehensive Cancer Network (2025). NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2, National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104528","DOI":"10.1016\/j.esmoop.2025.104528","article-title":"ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer","volume":"10","author":"Conroy","year":"2025","journal-title":"ESMO Open"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Linehan, A., O\u2019Reilly, M., McDermott, R., and O\u2019Kane, G.M. (2024). Targeting KRAS mutations in pancreatic cancer: Opportunities for future strategies. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1369136"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic developments in pancreatic cancer","volume":"21","author":"Hu","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: Advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s12672-025-03027-8","article-title":"Emerging therapeutic advancements in pancreatic cancer: A contemporary review","volume":"16","author":"Malla","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.18632\/oncotarget.27727","article-title":"A comprehensive analysis of clinical trials in pancreatic cancer: What is coming down the pike?","volume":"11","author":"Katayama","year":"2020","journal-title":"Oncotarget"},{"key":"ref_11","unstructured":"(2026, February 16). ClinicalTrials.gov [Internet], Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_12","unstructured":"World Health Organization (2026). Global Observatory on Health Research and Development: Clinical Trials [Internet], World Health Organization. Available online: https:\/\/www.who.int\/observatories\/global-observatory-on-health-research-and-development\/resources\/databases\/databases-on-processes-for-r-d\/clinical-trials."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Shenoy, A., Yousif, A., and Hussain, M.D. (2025). Recent advances and challenges in the treatment of advanced pancreatic cancer: An update on completed and ongoing clinical trials. Cancers, 17.","DOI":"10.3390\/cancers17081319"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111433","DOI":"10.3748\/wjg.v31.i43.111433","article-title":"Pancreatic cancer in 2025: Have we found a solution?","volume":"31","author":"Tonini","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.hpb.2019.12.001","article-title":"A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC)","volume":"22","author":"Kamarajah","year":"2020","journal-title":"HPB"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9255","DOI":"10.34172\/ijhpm.9255","article-title":"Federal funding and clinical trial sponsorship in pancreatic cancer from 2003 to 2022","volume":"15","author":"Mederos","year":"2026","journal-title":"Int. J. Health Policy Manag."},{"key":"ref_17","first-page":"MR000033","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: A randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_23","unstructured":"Gruppo Oncologico del Nord-Ovest (2026, July 15). Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients with Advanced Pancreatic Cancer. ClinicalTrials.gov. Identifier: NCT06897644, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06897644."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1200\/JCO.20.03329","article-title":"Randomized phase II trial evaluating two sequential treatments in first-line metastatic pancreatic cancer: Results of the PANOPTIMOX-PRODIGE 35 trial","volume":"39","author":"Dahan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_25","unstructured":"Sahlgrenska University Hospital (2026, July 15). Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR\/LAPC. ClinicalTrials.gov. Identifier: NCT06714604, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06714604."},{"key":"ref_26","unstructured":"CSPC Ouyi Pharmaceutical Co., Ltd. (2026, July 15). Liposomal Irinotecan in Combination with Oxaliplatin and S-1 Versus Gemcitabine Combined with Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer. ClinicalTrials.gov. Identifier: NCT06571461, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06571461."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): A multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC-01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Shen, H., Lundy, J., Strickland, A.H., Harris, M., Swan, M., Desmond, C., Jenkins, B.J., and Croagh, D. (2022). KRAS G12D mutation subtype in pancreatic ductal adenocarcinoma: Does it influence prognosis or stage of disease at presentation?. Cells, 11.","DOI":"10.3390\/cells11193175"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.32604\/or.2024.045356","article-title":"Targeting KRAS in pancreatic cancer","volume":"32","author":"Stickler","year":"2024","journal-title":"Oncol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","article-title":"Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_33","unstructured":"(2026, July 15). Resected Pancreatic Ductal Adenocarcinoma (PDAC). ClinicalTrials.gov. Identifier: NCT07252232, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07252232."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","article-title":"Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer","volume":"394","author":"Park","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_35","unstructured":"Astellas Pharma Global Development, Inc. (2026, July 15). A Study to Confirm the Safety of ASP3082, and if it Delays Tumor Growth in People with Pancreatic Cancer, When Given with Either mFOLFIRINOX or NALIRIFOX Chemotherapies. ClinicalTrials.gov. Identifier: NCT07409272, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07409272."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_37","unstructured":"University Health Network, Toronto (2026, July 15). Study of NABPLAGEM vs. Nab-Paclitaxel\/Gemcitabine in BRCA1\/2 or PALB2 Pancreatic Cancer. ClinicalTrials.gov. Identifier: NCT06783140, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06783140."},{"key":"ref_38","unstructured":"Alliance for Clinical Trials in Oncology (2026, July 15). The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1\/2 or PALB2-Associated Metastatic Pancreatic Cancer. ClinicalTrials.gov. Identifier: NCT06115499, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06115499."},{"key":"ref_39","unstructured":"Fudan University (2026, July 15). Cisplatin to Patients with Pancreatic Cancer and Homologous Recombination Deficiency. ClinicalTrials.gov. Identifier: NCT06095141, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06095141."},{"key":"ref_40","unstructured":"SWOG Cancer Research Network (2026, July 15). Studying Chemotherapy with or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations. ClinicalTrials.gov. Identifier: NCT06998940, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06998940."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205","volume":"28","author":"Philip","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_42","unstructured":"Arcus Biosciences, Inc. (2026, July 15). Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. ClinicalTrials.gov. Identifier: NCT06608927, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06608927."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1200\/JCO.2024.42.3_suppl.665","article-title":"ARC-8: Phase 1\/1b randomized study of quemliclustat plus gemcitabine\/nab-paclitaxel \u00b1 zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma","volume":"42","author":"Wainberg","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"npj Precis Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Thankachan, S.V., Jayaraman, V., Datta, L., Apthi, S., Zaman, B.F., Gurunathan, R., Suresh, A., Chandrakesan, P., Vinayagam, R., and Kang, S.G. (2025). Tumor microenvironment: Recent advances in immunotherapies of pancreatic cancer. Medicina, 61.","DOI":"10.3390\/medicina61101776"},{"key":"ref_47","unstructured":"West China Hospital (2026, July 15). A Phase III, Randomized, Clinical Trial of GnP Combined with SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients with Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006\/ICSBR-2). ClinicalTrials.gov. Identifier: NCT07336953, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07336953."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e084274","DOI":"10.1136\/bmjopen-2024-084274","article-title":"Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocarcinoma in China: A multicentre, single-arm, phase II trial (ICSBR) protocol","volume":"14","author":"Zhang","year":"2024","journal-title":"BMJ Open"},{"key":"ref_49","unstructured":"GC Cell Corporation (2026, July 15). Safety and Efficacy of Immuncell-LC with Gemcitabine in Resectable Pancreatic Cancer. ClinicalTrials.gov. Identifier: NCT04969731, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04969731."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Liang, K.L., and Azad, N.S. (2025). Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting. Cancers, 17.","DOI":"10.3390\/cancers17071246"},{"key":"ref_51","unstructured":"Georgetown University (2026, July 15). Evaluating Novel Therapies in ctDNA Positive GI Cancers. ClinicalTrials.gov. Identifier: NCT05482516, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05482516."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Theocharopoulos, C., Machairas, N., Ziogas, I.A., Mungo, B., Del Chiaro, M., Glatzounis, G.K., Schulick, R., and Sotiropoulos, G.C. (2026). Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making. Cancers, 18.","DOI":"10.3390\/cancers18010094"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"ref_54","unstructured":"NRG Oncology (2026, July 15). Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer. ClinicalTrials.gov. Identifier: NCT06958328, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06958328."},{"key":"ref_55","unstructured":"M.D. Anderson Cancer Center (2026, July 15). Extending Outcomes for Pancreas Cancer Patients with Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial. ClinicalTrials.gov. Identifier: NCT06593431, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06593431."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1200\/JCO.24.00081","article-title":"Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial","volume":"42","author":"Ludmir","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_57","unstructured":"Fudan University (2026, July 15). Radiotherapy to Patients with CA19-9-Elevated Advanced Pancreatic Cancer. ClinicalTrials.gov. Identifier: NCT06250972, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06250972."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"188409","DOI":"10.1016\/j.bbcan.2020.188409","article-title":"Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter","volume":"1875","author":"Luo","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_59","unstructured":"Erasmus Medical Center (2026, July 15). Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer. ClinicalTrials.gov. Identifier: NCT04927780, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04927780."},{"key":"ref_60","unstructured":"Minia University (2026, July 15). Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer. ClinicalTrials.gov. Identifier: NCT07081360, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07081360."},{"key":"ref_61","unstructured":"Minia University (2026, August 15). Tissue Adhesive Glue Modified Cyanoacrylate (Glubran\u00ae 2) in Soft Pancreas. ClinicalTrials.gov. Identifier: NCT07155525, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07155525."},{"key":"ref_62","unstructured":"Angiodynamics, Inc. (2026, August 15). A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer. ClinicalTrials.gov. Identifier: NCT03899636, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03899636."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1148\/radiol.2019191109","article-title":"Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer (PANFIRE-2): A multicenter, prospective, single-arm, phase II study","volume":"294","author":"Ruarus","year":"2020","journal-title":"Radiology"},{"key":"ref_64","unstructured":"Quercis Pharma, A.G. (2026, July 15). The Effect of Kinisoquin\u2122 on Thromboembolic Events in Patients with Metastatic or Locally Advanced Pancreatic Cancer. ClinicalTrials.gov. Identifier: NCT06861088, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06861088."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Prouse, T., Mohammad, M.A., Ghosh, S., Kumar, N., Duhaylungsod, M.L., Majumder, R., and Majumder, S. (2024). Pancreatic cancer and venous thromboembolism. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115661"},{"key":"ref_66","unstructured":"Fudan University (2026, July 15). Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer. ClinicalTrials.gov. Identifier: NCT06018883, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06018883."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s13063-024-08345-w","article-title":"Efficacy of vitamin C on chemotherapy-related anemia in pancreatic cancer: Study protocol for a randomized controlled trial","volume":"25","author":"Wang","year":"2024","journal-title":"Trials"},{"key":"ref_68","unstructured":"(2026, July 15). A Study to Learn About the Medicine Ponsegromab in Adults with Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue. ClinicalTrials.gov. Identifier: NCT06989437, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06989437."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","article-title":"Ponsegromab for the treatment of cancer cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Yoon, S.L., Grundmann, O., Rogers, S., Schlaeger, J.M., Han, B., Agyare, E., and Wilkie, D.J. (2025). Cachexia in pancreatic cancer: New insights to impact quality of life and survival. Nutrients, 17.","DOI":"10.3390\/nu17193064"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/bjr\/tqae217","article-title":"An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment","volume":"98","author":"Corallo","year":"2025","journal-title":"Br. J. Radiol."},{"key":"ref_72","unstructured":"GE Healthcare (2026, July 15). Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET\/CT for Detection of PC in Patients with Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE). ClinicalTrials.gov. Identifier: NCT07219238, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07219238."},{"key":"ref_73","unstructured":"KU Leuven (2026, July 15). Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-Associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types. ClinicalTrials.gov. Identifier: NCT06782412, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06782412."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1371\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:26:41Z","timestamp":1788452801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":73,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ph19091371"],"URL":"https:\/\/doi.org\/10.3390\/ph19091371","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}